Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01855503 · ClinicalTrials.gov registry record
Breast Cancer Molecular Analysis Protocol
A clinical trial, sponsored by Yale University.
- Completed
- Registry status
- 121
- Enrollment target
NCT01855503 is a clinical trial that has completed, run by Yale University. The registered enrollment target is 121 participants.
The verdict
NCT01855503 has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 121 participants
- Enrollment target
Study Summary
This is a molecular testing study for patients with metastatic breast cancer. The purpose of this study is to find defects in the DNA of the cancer that could potentially be treated with US Food and Drug Administration (FDA)approved or investigational drugs. For example, if your cancer has a mutation in the Epidermal Growth Factor Receptor (EGFR) gene (a mutation is a change int he DNA sequence of a gene) that makes this receptor "superactive" a drug that inhibits this receptor may also inhibit the growth of the cancer. If this genetic defect is not present in the cancer the same drug may not work. This EGFR gene mutation based patient selection for treatment has worked in lung cancer and we are testing its value in breast cancer. What drugs may be available against particular genetic abnormalities in the context of this clinical study will change over time.
Interventions
- PROCEDURE Core Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2013-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01855503
The ClinicalTrials.gov registry entry for NCT01855503 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Core Biopsy is the first listed.
NCT01855503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01855503 about?
NCT01855503 is a clinical study titled "Breast Cancer Molecular Analysis Protocol". This is a molecular testing study for patients with metastatic breast cancer. The purpose of this study is to find defects in the DNA of the cancer that could potentially be treated with US Food and Drug Administration (FDA)approved or investigational drugs. For example, if your cancer has a mutatio...
What is the current status of trial NCT01855503?
This trial is currently completed. The enrollment target is 121 participants. The study started on 2013-05.
What interventions are being tested in trial NCT01855503?
The interventions under investigation include: Core Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT01855503?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.